UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026
Utah Medical Products reported 3Q 2026 revenue of $8.6 million, down 12.1% year-over-year, driven by zero sales to its two formerly largest customers (PendoTECH and its prior China BPM distributor) and a 32.7% drop in Filshie Clip System sales. Despite the revenue decline, Q3 net income rose 5.9% to $2.8 million and diluted EPS climbed 6.8% to $0.876, helped by $936 lower G&A from reduced litigation and completed Femcare intangible amortization, plus the Orion Medical acquisition adding $619 in sales. Nine-month revenue fell 12.2% to $25.9 million with EPS down 5.3% to $2.537; management projects a full-year 2026 sales decline of roughly 7%, expecting easier fourth-quarter comparisons.
Key figures
- Eps
- 0.876
- Revenue
- 8621000
- Guidance
- Management projects full-year 2026 consolidated sales decline close to 7%, versus the 12.2% YTD decline through 9M 2026
- Revenue Yoy
- -12.1%
- Eps 9m
- 2.537
- Revenue 9m
- 25873000
- Net income 9m
- 8077000
- Net income q3
- 2787000
- Revenue yoy 9m
- -12.2%
- Gross margin q3
- 56.1%
- Gross profit q3
- 4840000
- Dividends paid 9m
- 2963000
- Net income yoy q3
- +5.9%
- Adjusted ebitda q3
- 3735000
- Operating income q3
- 2795000
- Operating margin q3
- 32.4%
- Cash and investments
- 85202000
- Orion acquisition cost
- 5011000
- Operating income yoy q3
- +7.0%
- Filshie sales decline q3
- -32.7%
- Lost customers q3 2025 sales
- 491000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.